Pro Life Medica Sp. z o.o.

Lublin 43 trials 7 recruiting

43 Registered trials

7 Currently recruiting

Organisation

Pro Life Medica Sp. z o.o.

Location

Lublin, Poland

Identifier

ORG-100047173

Address

Ul. Wladyslawa Kunickiego 26a, 20-412, Poland

Departments

"ETG Lublin Prof. Life Medica Sp. z o. o."
2215:ETG Lublin
Chronic pain
Dermatology Department
ETG Dębica
ETG Lublin
ETG Poniatowa
ETG Zamość
n/a
NA
Neurology
Orthopedics
PL10004: gastroenterology
PL10017:ETG Zamość
PL10045_ETG Zamosc
Pro Life Medica Sp z o o ETG Zamosc
Pro Life Medica Sp. z o.o ETG Lublin

Clinical trials at this site (43)

Search interface

Extension of a clinical trial to assess the safety of a study drug called "CORT125134" in the treatment of Cushing Syndrome Ended

2024-514079-17-00 Endogenous Cushing Syndrome 10 2020-05-28
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504718-31-00 Moderately to Severely Active Ulcerative Colitis 10 2019-10-19
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29
The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinic… Ended

2023-505875-56-00 Knee osteoarthritis 6 2025-05-21
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in… Ended

2024-510826-16-00 Rheumatoid Arthritis 5 2025-04-07
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended

2023-504942-75-01 Moderate to Severe Allergic Rhinitis/Rhinoconjunctiviti 5 2024-08-22
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera… Ended

2023-505433-27-00 Atopic Dermatitis 5 2024-08-13
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS) Ended

2023-503915-14-00 Primary Sjögren's Syndrome 4 2023-11-15
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Hypertriglyceridemia, Cardiovascular Diseases, Atherosc 5 2023-06-08
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15
Eptinezumab as Preventive Treatment of Migraine in Adults with Migraine Ended

2023-510183-12-00 Chronic migraine 5 2021-07-05
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended

2023-510426-33-00 Moderately to Severely Active Crohn's Disease 5 2018-09-27